; Novo Nordisk, Bagsvaerd, Denmark), which is structurally similar to the naturally occurring activated coagulation factor VII, is licensed for use in patients with haemophilia A or B and inhibitors to coagulation factors VIII or IX and acquired haemophilia. There is considerable interest in the 'off label' adjunctive use of rFVIIa in major haemorrhage. A single randomized study has indicated that rFVIIa reduces blood transfusion following blunt trauma [1] . Other evidence for use of rFVIIa as rescue therapy in major haemorrhage remains largely anecdotal. We present our experience from a UK teaching hospital of the use of rFVIIa as rescue therapy in four cases of major haemorrhage, following surgery and blunt trauma. The response to rFVIIa was not consistent and we discuss possible factors limiting its effectiveness.
Case 1: A 39-yr-old male with a variant of Marfan's syndrome had been anti-coagulated with warfarin following aortic valve and root replacement. He had also undergone repair of infra-renal and thoracoabdominal aneurysms and developed a rupture of an aortic patch graft aneurysm. He underwent emergency aneurysm repair, requiring a massive blood transfusion, and shortly afterwards returned to theatre for a laparotomy for abdominal compartment syndrome. rFVIIa 90 µg kg Ϫ1 was administered for continued bleeding unresponsive to conventional therapy in the intensive care unit (ICU, see Table 1 ). There was no immediate response, and considerable volumes of fresh frozen plasma (FFP), cryoprecipitate and platelets and three further doses of rFVIIa were administered over the next 11 h (see Table 1 ). Bleeding ceased approximately 2 h after his final dose of rFVIIa. Anti-coagulation was recommenced on the fourth ICU day, by which time the prothrombin time (PT) and activated partial thromboplastin time (APTT) had normalized. He was discharged home 3 months after admission.
Case 2: A 53-yr-old male sustained multiple injuries as a result of a 10 m fall onto concrete, including a compound occipital fracture, temporal contusion, subarachnoid and subdural haemorrhage, multiple rib fractures and pulmonary contusions, and a femoral fracture. He received cardiopulmonary resuscitation during 15 min of pulseless electrical activity, which responded to decompression of a tension pneumothorax. He bled considerably from his head wound and chest drain despite FFP and platelet transfusion (see Table 1 ), and 120 µg kg Ϫ1 of rFVIIa was administered prior to laparotomy. Two litres of blood was found in the abdomen and splenectomy was performed. Generalized oozing continued but a bleeding point was not identified. Correction of coagulopathy was advised prior to consideration of cardiothoracic intervention, and a further 120 µg kg Ϫ1 rFVIIa was administered following additional transfusion therapy. Bleeding rapidly declined and he stabilized. Unfortunately, the head injuries subsequently found on CT scanning were not amenable to neurosurgical intervention. He developed evidence of brain stem death, and organ harvest was performed approximately 24 h later.
Case 3: A 53-yr-old motorcyclist was involved in a collision with a van, sustaining major pelvic and soft tissue injuries, including disruption of the rectum. Over the first 10 days of treatment, he underwent two laparotomies and application of a pelvic external fixator. He had developed septic shock and acute renal failure by the time of his third visit to theatre for a re-exploration and repacking of his wound. He bled considerably intra-and postoperatively, despite transfusion therapy (see Table 1 ). A dose of 90 µg kg Ϫ1 rFVIIa was administered, but with no immediate response. After further FFP, cryoprecipitate and platelets, a dose of 120 µg kg Ϫ1 rFVIIa was given. The bleeding ceased abruptly. He remained in ICU for 51 days, and was discharged home 6 months after his original injuries.
Case 4: A 63-yr-old female underwent elective repair of a supra-renal inflammatory aortic aneurysm, with re-implantation of the left renal artery. Her operation was difficult and splenectomy also required. She was still bleeding when she returned to ICU, despite transfusion therapy (see Table 1 ). A dose of 120 µg kg Ϫ1 rFVIIa was administered, with some immediate improvement. She improved further with FFP, cryoprecipitate and platelet transfusion. Twelve hours later, laparotomy for abdominal compartment syndrome was required. No bleeding point was isolated, and generalized oozing persisted despite FFP and platelet administration. A dose of 120 µg kg Ϫ1 rFVIIa was again administered, and her bleeding stopped. She was discharged from ICU 10 days after her admission.
In these cases, the use of rFVIIa was intended to assist haemostasis when surgical and conventional transfusion therapy had failed. Common to the cases was the consumption and dilution of coagulation factors and platelets, acidosis and, in three of the cases, hypothermia, predisposing towards coagulopathic bleeding. The brain injury of the second case and sepsis and renal failure of the third case may also have contributed to coagulopathy. rFVIIa is believed to act specifically at sites of injury by forming a complex with exposed vessel wall tissue factor. This complex stimulates factor X-activation and thus thrombin generation on the surface of activated platelets [2] . High-dose administration may compensate for coagulation factor and platelet deficiencies in coagulopathic bleeding. Furthermore, a large 'thrombin burst' may enable a more stabilized fibrin plug to develop [2] . rFVIIa reduced blood transfusion after blunt trauma in a recent randomized trial [1] . In retrospective analyses, rFVIIa also reduced blood product requirement when used as rescue therapy for patients with intractable bleeding [3, 4] , but it did not affect mortality [4] .
We used rFVIIa in a variety of clinical situations, with variable timing, dosing, prior blood product administration and variable outcome. We failed to see a consistent immediate response to its administration. The contribution of four doses of 90 µg kg Ϫ1 rFVIIa to haemostasis in our first case was not clear. Decline in bleeding was most dramatic in the other cases following a second, 120 µg kg Ϫ1 dose. For rFVIIa to be effective, adequate viable platelets and coagulation factors should be circulating. It is possible that, particularly in our first and fourth cases, there had been inadequate platelet replacement and, probably in the third case, insufficient coagulation factor replacement prior to administration of the first dose of rFVIIa. Furthermore, all four patients were acidaemic and, with the exception of the third patient, hypothermic at the time of initial rFVIIa administration. The least acidaemic patient (Case 4) was the only patient to show any response to the initial dose of rFVIIa. Hypothermia reduces activity of coagulation factors and platelets, and acidosis also impairs coagulation [5] . In vitro, acidosis may produce a marked reduction in the activity of rFVIIa [5] . Adequate platelet and coagulation factor transfusion, timed to coincide with rFVIIa administration, and with avoidance of hypothermia and correction of acidaemia, may have improved the efficacy of rFVIIa in our case series. The optimal dose of rFVIIa as rescue therapy is unknown. It is possible that the 90 and 120 µg kg Ϫ1 doses we used were inadequate. In haemophiliac patients, a repeated dose of 90-110 µg kg Ϫ1 every 2 h for 24 h provides effective peroperative haemostasis [2] . However, a much higher initial dose of 200 µg kg Ϫ1 , followed by two doses of 100 µg kg
Ϫ1
, was effective in reducing blood transfusion requirement in blunt haemorrhagic trauma [1] .
Three patients survived major haemorrhage with variable responses to rFVIIa. The other patient succumbed to his brain injury, although haemostasis was achieved. In vitro evidence suggests that rFVIIa does not induce or enhance a hypercoagulable state [6] , and considering the severity of this patient's injuries, it is likely that rFVIIa administration was not an important factor in the evolution of his brain injury. However, the safety of rFVIIa administration in trauma associated with head injury is unproven, and cerebral sinus thrombosis following rFVIIa administration to a young poly-trauma patient has been attributed to increased tissue factor exposure resulting from minor brain injury [7] .
Our case series illustrates an unpredictable response to rFVIIa when used for major haemorrhage control in blunt trauma and surgery. Further randomizedcontrolled trials are required to establish the effectiveness of rFVIIa beyond its current licence, the optimal timing and dose of administration and, at approximately £4000 per 7.2 mg dose, its cost effectiveness. It is evident, however, that adequate management of platelet and clotting factor deficiencies, acidaemia and hypothermia are required to maximize the response to rFVIIa.
